Your session is about to expire
← Back to Search
Dietary Supplement
Nitric Oxide Supplement for Primary Ciliary Dyskinesia
N/A
Recruiting
Led By Ricardo A Mosquera, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Control Group: patients with no known chronic lung disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline,after beet juice consumption(2 hours after consumption)
Awards & highlights
Study Summary
This trial tests a dietary supplement to see if it can improve lung function and cilia movement in normal people and those with Primary ciliary dyskinesia.
Who is the study for?
This trial is for adults aged 18-99 with Primary Ciliary Dyskinesia (PCD) and healthy controls without chronic lung disease. It's not suitable for those with bleeding disorders, beet allergies, other pulmonary conditions like cystic fibrosis, or recent nasal surgeries/infections.Check my eligibility
What is being tested?
The study tests the effects of 'Beet-it Juice', a dietary supplement high in nitric oxide, on nasal and exhaled NO levels, ciliary beat frequency using video microscopy, and overall lung function through spirometry in PCD patients compared to healthy individuals.See study design
What are the potential side effects?
While not explicitly stated here, potential side effects may include reactions related to beet consumption such as red-colored urine/stools, low calcium levels if taken excessively, kidney damage when consumed in large amounts over time.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I do not have any chronic lung diseases.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after beet juice consumption(2 hours after consumption)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after beet juice consumption(2 hours after consumption)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in nasal FeNO as measured by using the NIOX MINO® Airway Inflammation Monitor
Change in nasal NO as measured by a chemiluminescence analyzer
Secondary outcome measures
Change in ciliary beat frequency as measured using high-speed video-microscopy (HSVM)
Change in lung function as measured by spirometry
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PCD GroupExperimental Treatment1 Intervention
Group II: Control GroupPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center, HoustonLead Sponsor
904 Previous Clinical Trials
320,940 Total Patients Enrolled
Ricardo A Mosquera, MDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
3 Previous Clinical Trials
423 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have any chronic lung diseases.I am between 18 and 99 years old.I have lung-related health issues or have had nasal or sinus surgery.I have a condition that causes me to bleed for a long time.You are allergic to beets.
Research Study Groups:
This trial has the following groups:- Group 1: PCD Group
- Group 2: Control Group
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger